Overview

FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
FGF-1 is being used for the treatment of patients with diabetic or venous stasis ulcers. Procedure includes topical administration of FGF-1 or placebo and evaluation of safety, pharmacokinetics, and wound improvement.
Phase:
Phase 1
Details
Lead Sponsor:
CardioVascular BioTherapeutics, Inc.
Collaborator:
Warren General Hospital